EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that patent number 12150931 was issued by the United States Patent and ...
manilatimes9d
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial” or the "Company”), a clinical-stage biopharmaceutical company focused on ...
Adial Pharmaceuticals Extends CEO Cary Claiborne’s Tenure
Adial Pharmaceuticals ( (ADIL) ) has shared an announcement.
Yahoo Finance9d
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
Adial Pharmaceuticals, Inc GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical ...
Benzinga.com9d
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
Adial Pharmaceuticals secured a new U.S. patent covering genotype combinations for its AUD treatment, AD04, extending protection to 2031. A completed PK study of AD04 demonstrated lower ...
Investing5d
Adial Pharmaceuticals revises CEO's compensation package
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in pharmaceutical preparations with a market capitalization of $7.5 million, has amended its employment ...
Nasdaq5d
Adial Pharmaceuticals Extends CEO Cary Claiborne’s Tenure
Adial Pharmaceuticals ( (ADIL)) has shared an announcement. Adial Pharmaceuticals has extended its CEO Cary Claiborne’s tenure with a new three-year employment agreement effective from December ...
Morningstar9d
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical ...
Investing5d
Adial Pharmaceuticals revises CEO's compensation package
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in pharmaceutical preparations with a market capitalization of $7.5 million, has amended its employment agreement ...